← Back to patent-cliff list
Bafrekalant
Tier C — Watch / tradeBafrekalant
Bayer
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KCNK9
Indications (approved)：Obstructive sleep apnoea syndrome
Regional status
US
-
EU
Phase II
2021-03-03
China
Phase I
2021-09-09
Japan
No progress
2021-05-11
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bafrekalant?
Approved indications include: Obstructive sleep apnoea syndrome.
When does the Bafrekalant patent expire?
No public expiry year is available for Bafrekalant yet; this page updates once verified.
How do I get a quote for Bafrekalant intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07